NCT04609319 - Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions

Lung Cancer

Interventions

DRUG

Dacomitinib

This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC

Trial Locations (14)

Beacon Hospital, Petaling Jaya

Pantai Hospital Kuala Lumpur, Kuala Lumpur

University Malaya Medical Centre, Kuala Lumpur

Internal Medicine, Chinese Academy of Medical Sciences Cancer Hospital, Beijing

Beijing Cancer Hospital, Beijing

Rajiv Gandhi Cancer Institute And Research Centre, New Delhi

The First hospital of Jilin University, Changchun

Hunan Provincial Tumor Hospital, Changsha

Henan Cancer Hospital, Zhengzhou

Guangdong Provincial People's Hospital, Guangzhou

The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou

West China Hospital of Sichuan University, Chengdu

Tata Memorial Center, Kolkata, Kolkata, West Bengal

The First Affiliated Hospital of China Medical University, Shenyang, Liaoning Province